Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06843148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Study acronym: AGL13
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date changed from estimate of Apr 2026 to Jun 22, 2026
    • Eligibility criteria expanded, about 47 words
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2025 to Apr 2026
    • Site details revised
    v3
  3. Start date: Apr 2025 to Sep 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks
Trial Details
NCT Number NCT06843148
Lead Sponsor Université de Sherbrooke
Collaborators: CHU de Quebec-Universite Laval, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Conditions
(from sponsor)		 Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
Related terms Fatty Liver
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov